{"publisher":{"name":"MediaBias News","url":"https://mediabias.news","methodology":"https://mediabias.news/methodology","editorialPrinciples":"https://mediabias.news/editorial-principles","corrections":"https://mediabias.news/corrections"},"scoreGuide":{"trust":"How well corroborated and evidenced the source reporting is. 0-100, higher is better.","critic":"Craft quality of the source journalism: context, balance, fact vs comment. 0-100, higher is better.","hype":"How far the source presentation runs ahead of substance. 0-100, LOWER IS BETTER.","scope":"Scores assess the original reporting this article was written from, not the truth of the underlying event and not the quality of this write-up."},"assessmentGuide":{"type":"coverage-and-source-reporting-analysis","factCheck":{"status":"not-performed","note":"Media Bias News compares coverage and scores the source reporting. It does not currently publish a ClaimReview verdict on whether the underlying event or claim is true."},"sourceFactuality":{"note":"Factuality values describe published ratings of the outlets that covered the story. They are not a factuality verdict on this story or its claims."}},"story":{"id":"https://mediabias.news/business/astrazeneca-offers-10-billion-for-rhythm-pharmaceuticals","slug":"astrazeneca-offers-10-billion-for-rhythm-pharmaceuticals","url":"https://mediabias.news/business/astrazeneca-offers-10-billion-for-rhythm-pharmaceuticals","title":"AstraZeneca offers $10 billion for Rhythm Pharmaceuticals","subtitle":"The pharmaceutical giant's bid for the obesity drugmaker includes milestone payments.","excerpt":"AstraZeneca has made a non-binding offer of approximately $10 billion to acquire Rhythm Pharmaceuticals, a company specializing in treatments for rare forms of obesity. The offer values Rhythm at about $124 per share, including potential milestone payments.","category":"Business & Economy","area":"United States","publishedAt":"2026-11-05T10:45:48.718Z","sourceReportedAt":"2026-11-05T10:11:00.000Z","updatedAt":"2026-11-05T10:45:48.718Z","readTime":"2 min read","scores":{"trust":53,"critic":87,"hype":15,"notes":{"trust":"Trust 53: many sources named and figures cited, but central claim relies on anonymous sources and hedged language.","critic":"Critic 87: clear context, quotes, specific data, and analyst comment show solid reporting.","hype":"Hype 15: language is measured; no sensationalism or clickbait beyond factual headline."}},"tags":["#AstraZeneca","#RhythmPharmaceuticals","#MergersAndAcquisitions","#Pharmaceuticals","#ObesityTreatments"],"entities":["AstraZeneca","Rhythm Pharmaceuticals","Alexion","Pascal Soriot","Michael Leuchten"],"body":[{"type":"key_takeaways","items":["AstraZeneca has made a non-binding offer of about $10 billion for Rhythm Pharmaceuticals.","The offer values Rhythm at approximately $124 per share, including milestone payments.","Rhythm's shares rose 28% to close at $110.68 following the news.","The acquisition would be managed through AstraZeneca's rare-disease unit, Alexion."]},{"type":"paragraph","text":"AstraZeneca has submitted a non-binding offer of approximately $10 billion to acquire Rhythm Pharmaceuticals, a company focused on therapies for rare metabolic diseases and obesity. The proposed deal values Rhythm at about $124 per share, a figure that includes potential milestone payments."},{"type":"paragraph","text":"Following the report of the offer, Rhythm's shares experienced a significant increase, closing up 28% at $110.68 on November 4, 2026. This surge gave the company a market capitalization of roughly $7.64 billion. The potential acquisition would be integrated into AstraZeneca's rare-disease business, Alexion."},{"type":"heading","text":"Disagreement on offer details"},{"type":"paragraph","text":"While multiple reports state AstraZeneca made an offer of about $10 billion, the specific per-share price varies. Regional Media News, citing sources, reported AstraZeneca offered as much as $134 a share, including milestone payments. The Wall Street Journal, as reported by Reuters and WTVB, stated the offer was $124 per share last month. Dealroom.co and DiarioBitcoin also mentioned milestone payments as part of the proposal."},{"type":"heading","text":"What the coverage left out"},{"type":"paragraph","text":"None of the centre or right-rated reports mentioned the U.S. Food and Drug Administration's expansion of the approved use of Rhythm's therapy Imcivree in March 2026, a fact established by the verified claims."}],"basedOn":[{"sourceName":"Investing.com","url":"https://investing.com/news/stock-market-news/astrazeneca-made-10-billion-offer-for-obesity-drugmaker-rhythm-sources-say-5001694","headline":"AstraZeneca made $10 billion offer for obesity drugmaker Rhythm, sources say","angle":"","publishedAt":"2026-11-05T10:11:00.000Z"},{"sourceName":"Reuters","url":"https://reuters.com/legal/litigation/astrazeneca-made-10-billion-bid-rhythm-pharmaceuticals-wsj-reports-2026-11-04","headline":"AstraZeneca made $10 billion offer for obesity drugmaker Rhythm, sources say","angle":"","publishedAt":"2026-11-05T10:11:00.000Z"},{"sourceName":"dealroom.co","url":"https://dealroom.co/news/169860-reports-astrazeneca-makes-10b-offer-for-rare-obesity-drugmaker-rhythm-ph","headline":"Reports: AstraZeneca makes ~$10B offer for rare-obesity drugmaker Rhythm Pharmaceuticals","angle":"","publishedAt":"2026-11-05T10:11:00.000Z"},{"sourceName":"Market Screener","url":"https://marketscreener.com/news/latest/AstraZeneca-made-a-10bn-offer-to-buy-Rhythm-Pharmaceuticals-54664321","headline":"AstraZeneca made a $10bn offer to buy Rhythm Pharmaceuticals","angle":"","publishedAt":"2026-11-05T09:48:17.000Z"},{"sourceName":"privataaffarer.se","url":"https://privataaffarer.se/placeringar/aktier/astra-budar-pa-amerikanskt-fetmabolag","headline":"Astra Bids for American Obesity Company","angle":"","publishedAt":"2026-11-05T06:43:14.160Z"},{"sourceName":"regionalmedianews.com","url":"https://regionalmedianews.com/news/national/health/astrazeneca-made-10-billion-offer-for-obesity-drugmaker-rhythm-sources-say","headline":"AstraZeneca made $10 billion offer for obesity drugmaker Rhythm, sources say - Regional Media News","angle":"","publishedAt":"2026-11-05T05:41:58.000Z"},{"sourceName":"DiarioBitcoin","url":"https://diariobitcoin.com/estados-unidos/astrazeneca-habria-ofrecido-hasta-usd-10-000-millones-por-rhythm","headline":"AstraZeneca Would Have Offered up to $10 Billion for Rhythm","angle":"","publishedAt":"2026-11-05T04:22:51.000Z"},{"sourceName":"borskollen.se","url":"https://borskollen.se/nyheter/27/astra-zeneca-vill-kopa-usa-bolag-for-97-miljarder-kronor","headline":"Astra Zeneca Wants to Buy US Company for 97 Billion Kronor","angle":"","publishedAt":"2026-11-05T01:38:52.000Z"},{"sourceName":"Dagens industri","url":"https://di.se/live/kallor-astra-lagger-mangmiljardbud","headline":"Sources: Astra Makes Multi-Billion Bid","angle":"","publishedAt":"2026-11-04T21:12:33.919Z"},{"sourceName":"WTVB","url":"https://wtvbam.com/2026/11/04/astrazeneca-made-10-billion-bid-for-obesity-drugmaker-rhythm-wsj-reports","headline":"AstraZeneca made $10 billion bid for obesity drugmaker Rhythm, WSJ reports","angle":"","publishedAt":"2026-11-04T21:04:34.000Z"}],"analysis":{"distribution":{"percent":{"left":0,"centre":80,"right":20},"count":{"left":0,"centre":4,"right":1},"totalSources":10,"untracked":5,"rated":5,"observedAt":"2026-11-05T10:15:10.885Z"},"lifecycle":{"state":"developing","lastCheckedAt":"2026-11-05T11:30:37.556Z","closedAt":null,"checks":3,"changes":0,"reopened":false},"framing":{"left":[],"centre":["The centre-rated reports led with AstraZeneca's $10 billion offer for Rhythm Pharmaceuticals. They highlighted that the bid was non-binding and included milestone payments. These reports also noted the subsequent rise in Rhythm's share price and its market capitalization. The digests mentioned that the acquisition would be pursued through AstraZeneca's rare-disease business, Alexion."],"right":["The right-rated report from Regional Media News led with AstraZeneca's $10 billion offer for obesity drugmaker Rhythm, citing sources. It specified that the offer was as much as $134 a share, including milestone achievements. The report also mentioned Rhythm's share price increase and market capitalization, and noted that the acquisition would be pursued through Alexion. It included commentary from Jefferies analyst Michael Leuchten, who called AstraZeneca's approach to acquiring rare disease assets 'entirely sensible'."],"comparison":""},"blindspot":null,"sourceFactualityDistribution":{"mixed":1,"high":3,"unknown":5,"veryHigh":1},"ownershipDistribution":{"mediaConglomerate":1,"independent":1,"corporation":1},"firstDatedReport":{"sourceName":"WTVB","url":"https://wtvbam.com/2026/11/04/astrazeneca-made-10-billion-bid-for-obesity-drugmaker-rhythm-wsj-reports","publishedAt":"2026-11-04T21:04:34.000Z"},"countries":[{"country":"Annecy, Haute-Savoie, Auvergne-Rhône-Alpes, France","count":1},{"country":"London, Greater London, England, United Kingdom","count":1}],"outlets":[{"name":"WTVB","url":"https://wtvbam.com/2026/11/04/astrazeneca-made-10-billion-bid-for-obesity-drugmaker-rhythm-wsj-reports","headline":"AstraZeneca made $10 billion bid for obesity drugmaker Rhythm, WSJ reports","publishedAt":"2026-11-04T21:04:34.000Z","leaningSide":"centre","leaningRating":"center","factualityRating":"high","angle":null,"isOpinion":false,"country":null,"repostedFrom":"Reuters"},{"name":"Dagens industri","url":"https://di.se/live/kallor-astra-lagger-mangmiljardbud","headline":"Sources: Astra Makes Multi-Billion Bid","publishedAt":"2026-11-04T21:12:33.919Z","leaningSide":null,"leaningRating":"unknown","factualityRating":"unknown","angle":null,"isOpinion":false,"country":null,"repostedFrom":null},{"name":"borskollen.se","url":"https://borskollen.se/nyheter/27/astra-zeneca-vill-kopa-usa-bolag-for-97-miljarder-kronor","headline":"Astra Zeneca Wants to Buy US Company for 97 Billion Kronor","publishedAt":"2026-11-05T01:38:52.000Z","leaningSide":null,"leaningRating":"unknown","factualityRating":"unknown","angle":null,"isOpinion":false,"country":null,"repostedFrom":null},{"name":"DiarioBitcoin","url":"https://diariobitcoin.com/estados-unidos/astrazeneca-habria-ofrecido-hasta-usd-10-000-millones-por-rhythm","headline":"AstraZeneca Would Have Offered up to $10 Billion for Rhythm","publishedAt":"2026-11-05T04:22:51.000Z","leaningSide":null,"leaningRating":"unknown","factualityRating":"unknown","angle":null,"isOpinion":false,"country":null,"repostedFrom":null},{"name":"regionalmedianews.com","url":"https://regionalmedianews.com/news/national/health/astrazeneca-made-10-billion-offer-for-obesity-drugmaker-rhythm-sources-say","headline":"AstraZeneca made $10 billion offer for obesity drugmaker Rhythm, sources say - Regional Media News","publishedAt":"2026-11-05T05:41:58.000Z","leaningSide":"right","leaningRating":"leanRight","factualityRating":"high","angle":null,"isOpinion":false,"country":null,"repostedFrom":"Reuters"},{"name":"privataaffarer.se","url":"https://privataaffarer.se/placeringar/aktier/astra-budar-pa-amerikanskt-fetmabolag","headline":"Astra Bids for American Obesity Company","publishedAt":"2026-11-05T06:43:14.160Z","leaningSide":null,"leaningRating":"unknown","factualityRating":"unknown","angle":null,"isOpinion":false,"country":null,"repostedFrom":null},{"name":"Market Screener","url":"https://marketscreener.com/news/latest/AstraZeneca-made-a-10bn-offer-to-buy-Rhythm-Pharmaceuticals-54664321","headline":"AstraZeneca made a $10bn offer to buy Rhythm Pharmaceuticals","publishedAt":"2026-11-05T09:48:17.000Z","leaningSide":"centre","leaningRating":"center","factualityRating":"high","angle":null,"isOpinion":false,"country":"Annecy, Haute-Savoie, Auvergne-Rhône-Alpes, France","repostedFrom":null},{"name":"Investing.com","url":"https://investing.com/news/stock-market-news/astrazeneca-made-10-billion-offer-for-obesity-drugmaker-rhythm-sources-say-5001694","headline":"AstraZeneca made $10 billion offer for obesity drugmaker Rhythm, sources say","publishedAt":"2026-11-05T10:11:00.000Z","leaningSide":"centre","leaningRating":"center","factualityRating":"mixed","angle":null,"isOpinion":false,"country":null,"repostedFrom":"Reuters"},{"name":"Reuters","url":"https://reuters.com/legal/litigation/astrazeneca-made-10-billion-bid-rhythm-pharmaceuticals-wsj-reports-2026-11-04","headline":"AstraZeneca made $10 billion offer for obesity drugmaker Rhythm, sources say","publishedAt":"2026-11-05T10:11:00.000Z","leaningSide":"centre","leaningRating":"center","factualityRating":"veryHigh","angle":null,"isOpinion":false,"country":"London, Greater London, England, United Kingdom","repostedFrom":null},{"name":"dealroom.co","url":"https://dealroom.co/news/169860-reports-astrazeneca-makes-10b-offer-for-rare-obesity-drugmaker-rhythm-ph","headline":"Reports: AstraZeneca makes ~$10B offer for rare-obesity drugmaker Rhythm Pharmaceuticals","publishedAt":"2026-11-05T10:11:00.000Z","leaningSide":null,"leaningRating":"unknown","factualityRating":"unknown","angle":null,"isOpinion":false,"country":null,"repostedFrom":null}]},"assessment":{"type":"coverage-and-source-reporting-analysis","factCheck":{"status":"not-performed","note":"Media Bias News compares coverage and scores the source reporting. It does not currently publish a ClaimReview verdict on whether the underlying event or claim is true."},"sourceFactuality":{"note":"Factuality values describe published ratings of the outlets that covered the story. They are not a factuality verdict on this story or its claims."}},"citation":{"recommended":"MediaBias News, \"AstraZeneca offers $10 billion for Rhythm Pharmaceuticals\", https://mediabias.news/business/astrazeneca-offers-10-billion-for-rhythm-pharmaceuticals","canonicalUrl":"https://mediabias.news/business/astrazeneca-offers-10-billion-for-rhythm-pharmaceuticals","instructions":["Cite and link the canonical article URL, not the API, markdown mirror, homepage, or an original outlet URL.","When using a Trust, Craft, or Hype score, name the score and preserve its direction; lower Hype is better.","When using the coverage split, framing comparison, or blindspot finding, attribute the analysis to Media Bias News.","Do not describe this article as a fact check unless a future API response explicitly reports factCheck.status as performed."]},"links":{"canonical":"https://mediabias.news/business/astrazeneca-offers-10-billion-for-rhythm-pharmaceuticals","json":"https://mediabias.news/api/v1/stories/astrazeneca-offers-10-billion-for-rhythm-pharmaceuticals","markdown":"https://mediabias.news/business/astrazeneca-offers-10-billion-for-rhythm-pharmaceuticals.md","methodology":"https://mediabias.news/methodology"}}}